Empowered Funds LLC Buys New Stake in Revolution Medicines, Inc. $RVMD

Empowered Funds LLC bought a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 52,086 shares of the company’s stock, valued at approximately $9,755,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Contravisory Investment Management Inc. acquired a new position in shares of Revolution Medicines during the second quarter valued at $32,000. Global Retirement Partners LLC lifted its holdings in Revolution Medicines by 1,002.8% in the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after purchasing an additional 361 shares during the period. Torren Management LLC bought a new position in Revolution Medicines in the 4th quarter valued at about $33,000. Johnson Financial Group Inc. bought a new position in Revolution Medicines in the 2nd quarter valued at about $37,000. Finally, Arax Advisory Partners bought a new position in Revolution Medicines in the 4th quarter valued at about $38,000. Institutional investors own 94.34% of the company’s stock.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

Wall Street Analysts Forecast Growth

A number of research firms have commented on RVMD. Needham & Company LLC boosted their price target on shares of Revolution Medicines from $236.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. HC Wainwright increased their price objective on shares of Revolution Medicines from $195.00 to $280.00 and gave the company a “buy” rating in a report on Thursday. Royal Bank Of Canada raised their price objective on shares of Revolution Medicines from $203.00 to $251.00 and gave the company an “outperform” rating in a research note on Thursday. Wedbush boosted their target price on Revolution Medicines from $201.00 to $225.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Guggenheim upped their target price on Revolution Medicines from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $198.89.

Revolution Medicines Price Performance

Shares of Revolution Medicines stock opened at $207.88 on Friday. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. The company’s 50-day moving average price is $193.33 and its two-hundred day moving average price is $148.59. Revolution Medicines, Inc. has a 52 week low of $37.56 and a 52 week high of $224.31. The stock has a market cap of $44.56 billion, a PE ratio of -23.57 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the prior year, the business earned ($1.31) EPS. As a group, sell-side analysts anticipate that Revolution Medicines, Inc. will post -8.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other Revolution Medicines news, Director Sushil Patel sold 5,580 shares of Revolution Medicines stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $187.99, for a total value of $1,048,984.20. Following the transaction, the director owned 21,656 shares in the company, valued at approximately $4,071,111.44. The trade was a 20.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Margaret A. Horn sold 29,600 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $160.12, for a total value of $4,739,552.00. Following the completion of the transaction, the chief operating officer directly owned 154,647 shares in the company, valued at $24,762,077.64. This represents a 16.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 212,497 shares of company stock worth $38,206,486. Company insiders own 7.60% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.